Kyle M. Kampman, MD

Psychiatry
Sees patients age 18 and up
Penn Treatment Research Center
Headshot of Kyle M. Kampman, MD
Penn Medicine Provider

About me

  • Professor of Psychiatry at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

My education and training

  • Medical School: Tulane University School of Medicine
  • Residency: National Naval Med Center
  • Residency: University of Pennsylvania Health System
  • Fellowship: VA Medical Center

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Kampman is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Vickers-Smith R, Crist RC, Kember RL, Kampman KM, Justice A; VA Million Veteran Program; Kranzler HR. Racial and ethnic disparities in buprenorphine retention and treatment outcome in a longitudinal cohort of U.S. veterans with opioid use disorder , Am J Drug Alcohol Abuse: 2026


White DM, Kimmel PL, Dember LM, Wilkie C, Edwards DP, Williams J, Bernardo L, Quintana N, Cheatle MD, Lash JP, Fischer MJ, Schmidt R, Doorenbos A, Schrauben S, Johansen KL; HOPE Consortium, a member of the HEAL Initiative. Patient Engagement in the Design and Conduct of the HOPE Trial: Addressing Chronic Pain in Hemodialysis Patients , Clin J Am Soc Nephrol, 20: 2025,1461-1469


Dember LM, Hsu JY, Mehrotra R, Cavanaugh KL, Kalim S, Charytan DM, Fischer MJ, Jhamb M, Johansen KL, Becker WC, Pellegrino B, Eneanya ND, Schrauben SJ, Pun PH, Unruh ML, Morasco BJ, Mehta M, Miyawaki N, Penfield J, Bernardo L, Brintz CE, Cheatle MD, Doorenbos AZ, Heapy AA, Keefe FJ, Krebs EE, Kuzla N, Nigwekar SU, Schmidt RJ, Steel JL, Wetmore JB, White DM, Kimmel PL, Cukor D; HOPE Consortium. Pain Coping Skills Training for Patients Receiving Hemodialysis: The HOPE Consortium Randomized Clinical Trial , JAMA Intern Med, 185: 2025,197-207


Davis CN, Khan Y, Crist RC, Vickers-Smith R, Hartwell EE, Gelernter J, Kampman K, Kember RL, Le Moigne A, Laffont CM, Kranzler HR. Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response , Neuropsychopharmacology: 2025


Kurz M, Guerra-Alejos BC, Min JE, Seaman SR, Piske M, Bach P, Bruneau J, Greenland S, Gustafson P, Kampman K, Karim ME, Korthuis PT, Platt RW, Siebert U, Socías ME, Wood E, Nosyk B. Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population-based target trial in British Columbia, Canada , Addiction: 2025


Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R, Piske M, Seaman SR, Bach P, Greenland S, Karim ME, Siebert U, Bruneau J, Gustafson P, Kampman K, Korthuis PT, Loughin T, McCandless LC, Platt RW, Schnepel KT, Socías ME. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder , JAMA: 2024


Thakrar AP, Christine PJ, Siaw-Asamoah A, Spadaro A, Faude S, Snider CK, Delgado MK, Lowenstein M, Kampman K, Perrone J, Nelson LS, Kilaru AS. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl , JAMA Netw Open, 7: 2024,e2435895


Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD. Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder , J Clin Psychiatry, 84: 2023,22br14567


Stewart RE, Cardamone NC, Mandell DS, Kwon N, Kampman KM, Knudsen HK, Tjoa CW, Marcus SC. Not in my treatment center: Leadership's perception of barriers to MOUD adoption , J Subst Abuse Treat: 2023


Krouse RA, Morales KH, Kampman KM, Chakravorty S. The role of baseline insomnia in moderating the hypnotic properties of quetiapine , Addict Behav: 2023